Tumor News and Research

RSS

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Genoptix, Inc., a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it.

19 Feb 2010

Scientists develop new way to make simple oil droplets smart enough to navigate through complex maze

Call them oil droplets with a brain or even "chemo-rats." Scientists in Illinois have developed a way to make simple oil droplets "smart" enough to navigate through a complex maze almost like a trained lab rat. The finding could have a wide range of practical implications, including helping cancer drugs to reach their target and controlling the movement of futuristic nano-machines, the scientists say.

19 Feb 2010

Most genetic abnormalities shared across multiple cancers

An international team of researchers has created a genome-scale map of 26 different cancers, revealing more than 100 genomic sites where DNA from tumors is either missing or abnormally duplicated compared to normal tissues. The study, the largest of its kind, finds that most of these genetic abnormalities are not unique to one form of cancer, but are shared across multiple cancers. The work appears in the February 18 issue of the journal Nature.

19 Feb 2010

AGH neurosurgeons explore new therapeutic approach for brain tumor

Neurosurgeons at Allegheny General Hospital (AGH) are exploring use of a drug that illuminates brain tumor cells to determine if the experimental visualization technique will enhance their ability to surgically excise tumors and improve patient survival.

19 Feb 2010

Researchers use Life Technologies’ next-generation sequencing instruments for cancer research

Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.

19 Feb 2010

Research shows natural compound in marine sponges reduces cancer cell motility

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research) led by Kristiina Vuori, M.D., Ph.D., have discovered that the natural compound sceptrin, which is found in marine sponges, reduces cancer cell motility (movement) and has very low toxicity.

19 Feb 2010

ATM tumor-suppressor also recognizes damage caused by ROS and orders autophagy

ATM, a protein that reacts to DNA damage by ordering repairs or the suicide of the defective cell, plays a similar, previously unknown role in response to oxidative damage outside of the nucleus, researchers report this week in the online version of the Proceedings of the National Academy of Sciences.

19 Feb 2010

New endoscopic ablation technique safe and effective for treating Barrett's esophagus

Early tumor formation in Barrett's esophagus (BE) can be effectively and safely treated with radiofrequency ablation (RFA), in combination with prior endoscopic removal of visible lesions, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

19 Feb 2010

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Van Andel Research Institute researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

19 Feb 2010

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Scientists at the Johns Hopkins Kimmel Cancer Center have used data from the whole genome sequencing of cancer patients to develop individualized blood tests they believe can help physicians tailor patients' treatments. The genome-based blood tests, believed to be the first of their kind, may be used to monitor tumor levels after therapy and determine cancer recurrence.

19 Feb 2010

Cellular metabolism plays a key role in cancer development

It is not unusual to hear people blame their metabolism after gaining a few pounds. But changes in metabolism - the process that shapes how our bodies turn food into energy -- can have much more sinister effects than making it hard to fit into your favorite jeans.

19 Feb 2010

RainDance Technologies enters into strategic agreement with Applied Biosystems

RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, and Applied Biosystems, part of Life Technologies Corporation, announced today they have entered into a strategic agreement to co-market the first solution that combines microdroplet PCR-based sequence enrichment with next-generation sequencing.

19 Feb 2010

Researchers find gene mutations that may provide clues for treating AML patients

Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin.

19 Feb 2010

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

The Methodist Hospital Research Institute was awarded an $11.5 million Center Grant by the National Institutes for Health (NIH) today to study the best way to attack deadly cancer stem cells to enhance treatments for breast cancer. Other members of the team include Baylor College of Medicine and the University of Texas Health Science Center at Houston.

19 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

NPG becomes official media partner to the 2010 WIN Symposium

Nature Publishing Group (NPG) is the official media partner to the 2010 WIN (Worldwide Innovative Networking) Symposium, it was announced today. The second annual WIN Symposium, which will be held in the Palais des Congrès, Paris, 7–9 July 2010, will bring together hundreds of oncology researchers from around the world to discuss how best to tailor therapies for patients with cancer.

18 Feb 2010

Nanotechnology plays a key role in detection and treatment of cancer

A world-renowned medical researcher discusses the key role that nanotechnology has begun to play in the detection and treatment of cancer in an article that will appear in the March 2010 edition of Mechanical Engineering magazine.

18 Feb 2010

Researchers discover new prognosis marker for prostate cancer

Measuring levels of the active form of the protein EGFR in the tumor and its vicinity can provide a more reliable prognosis for individuals with prostate cancer.

18 Feb 2010

Tumor News and Research

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Scientists develop new way to make simple oil droplets smart enough to navigate through complex maze

Most genetic abnormalities shared across multiple cancers

AGH neurosurgeons explore new therapeutic approach for brain tumor

Researchers use Life Technologies’ next-generation sequencing instruments for cancer research

Research shows natural compound in marine sponges reduces cancer cell motility

ATM tumor-suppressor also recognizes damage caused by ROS and orders autophagy

New endoscopic ablation technique safe and effective for treating Barrett's esophagus

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Cellular metabolism plays a key role in cancer development

RainDance Technologies enters into strategic agreement with Applied Biosystems

Researchers find gene mutations that may provide clues for treating AML patients

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

Rituxan, intended for patients with CLL receives FDA approval

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Antigenics announces fourth-quarter and full-year 2009 financial results

NPG becomes official media partner to the 2010 WIN Symposium

Nanotechnology plays a key role in detection and treatment of cancer

Researchers discover new prognosis marker for prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News